{"entity":{"id":"sc-102","kind":"drug","name":"SC-102","aka":[],"tldr":"SC-102 is an experimental peptide-drug conjugate from ConjuStar Biologics, in phase 1 trials for ephA2-expressing advanced or metastatic solid tumours.","summary":"SC-102 is a peptide-drug conjugate from ConjuStar Biologics. A peptide-drug conjugate made of an EphA2-targeting peptide, a tubulin-inhibitor payload and a protease-cleavable linker. Its furthest stage is phase 1, for ephA2-expressing advanced or metastatic solid tumours. ClinicalTrials.gov registers it in one study linked below. US FDA IND clearance announced 4 June 2025 (company news); phase 1 recruiting (NCT06710158). Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"ConjuStar Biologics: conjustar.com","url":"https://www.conjustar.com/"},{"label":"ConjuStar Biologics: clinicaltrials.gov","url":"https://clinicaltrials.gov/study/NCT06710158"},{"label":"ClinicalTrials.gov: trials of SC-102","url":"https://clinicaltrials.gov/search?intr=SC-102"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":["epha2"],"drugs":[],"companies":["conjustar-biologics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06710158"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"SC-102","modality":"Peptide-drug conjugate","mechanism":"A peptide-drug conjugate made of an EphA2-targeting peptide, a tubulin-inhibitor payload and a protease-cleavable linker.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/sc-102/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"target":[{"id":"epha2","kind":"target","name":"EphA2 receptor","route":"/targets/epha2/"}],"company":[{"id":"conjustar-biologics","kind":"company","name":"ConjuStar Biologics","route":"/companies/conjustar-biologics/"}],"trial":[{"id":"nct06710158","kind":"trial","name":"Study of SC-102 in Patients With Advanced Solid Tumors","route":"/trials/nct06710158/"}]}}